SYMTUZA Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Symtuza, and when can generic versions of Symtuza launch?
Symtuza is a drug marketed by Janssen Prods and is included in one NDA. There are eight patents protecting this drug and one Paragraph IV challenge.
This drug has four hundred and eighty-five patent family members in fifty-one countries.
The generic ingredient in SYMTUZA is cobicistat; darunavir; emtricitabine; tenofovir alafenamide fumarate. There are five drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the cobicistat; darunavir; emtricitabine; tenofovir alafenamide fumarate profile page.
DrugPatentWatch® Generic Entry Outlook for Symtuza
Symtuza was eligible for patent challenges on November 5, 2019.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be October 6, 2032. This may change due to patent challenges or generic licensing.
There have been thirty patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.
Indicators of Generic Entry
Summary for SYMTUZA
International Patents: | 485 |
US Patents: | 8 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Clinical Trials: | 5 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for SYMTUZA |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for SYMTUZA |
What excipients (inactive ingredients) are in SYMTUZA? | SYMTUZA excipients list |
DailyMed Link: | SYMTUZA at DailyMed |
![SYMTUZA drug patent expirations Drug patent expirations by year for SYMTUZA](/p/graph/s/t/SYMTUZA-patent-expirations.png)
![Drug Prices for SYMTUZA](/p/graph/drug-price/SYMTUZA.png)
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for SYMTUZA
Generic Entry Date for SYMTUZA*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for SYMTUZA
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
East Carolina University | Phase 4 |
Imperial College London | Phase 3 |
Chelsea and Westminster NHS Foundation Trust | Phase 3 |
Pharmacology for SYMTUZA
Anatomical Therapeutic Chemical (ATC) Classes for SYMTUZA
Paragraph IV (Patent) Challenges for SYMTUZA
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
SYMTUZA | Tablets | cobicistat; darunavir; emtricitabine; tenofovir alafenamide fumarate | 800 mg/150 mg/ 200 mg/10 mg | 210455 | 1 | 2021-08-16 |
US Patents and Regulatory Information for SYMTUZA
SYMTUZA is protected by fifteen US patents.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of SYMTUZA is ⤷ Try a Trial.
This potential generic entry date is based on patent ⤷ Try a Trial.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting SYMTUZA
Use of solid carrier particles to improve the processability of a pharmaceutical agent
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Compositions and methods of treating HIV
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TREATMENT OF HIV-1 INFECTION IN ADULT OR PEDIATRIC PATIENTS (>=40 KG) WITH = 6 MONTHS ON PRIOR ANTIRETROVIRAL REGIMEN AND NO KNOWN DARUNAVIR OR TENOFOVIR RESISTANCE-ASSOCIATED SUBSTITUTIONS
Prodrugs of phosphonate nucleotide analogues
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Pseudopolymorphic forms of a HIV protease inhibitor
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Modulators of pharmacokinetic properties of therapeutics
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TX OF HIV-1 INFECTION USING A COMPOSITION CONTAINING A PK ENHANCER THAT INHIBITS CYTOCHROME P450 MONOOXYGENATES IN ADULTS WHO HAVE NO PRIOR ANTIRETROVIRAL TX HISTORY OR ARE VIROLOGICALLY SUPPRESSED ON A STABLE ANTIRETROVIRAL REGIMEN FOR AT LEAST 6 MONTHS
Modulators of pharmacokinetic properties of therapeutics
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TREATMENT OF HIV-1 INFECTION USING A COMPOSITION CONTAINING A PK ENHANCER THAT INHIBITS CY P450 MONOXYGENASE IN ADULTS AND PEDIATRIC PATIENTS WEIGHING AT LEAST 40KG WHO HAVE NO PRIOR ARV TREATMENT HISTORY
Modulators of pharmacokinetic properties of therapeutics
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TREATMENT OF HIV-1 INFECTION USING A COMPOSITION CONTAINING A PK ENHANCER THAT INHIBITS CY P450 MONOXYGENASE IN ADULTS AND PEDIATRIC PATIENTS WEIGHING AT LEAST 40KG WHO ARE VIROLOGICALLY SUPPRESSED ON A STABLE ARV REGIMEN FOR AT LEAST 6 MONTHS
Modulators of pharmacokinetic properties of therapeutics
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TX OF HIV1 INFECTION USING A COMPOSITION CONTAINING A PK ENHANCER THAT INHIBITS CY P450 MONOXYGENASE IN ADULTS & PEDIATRIC PATIENTS AT LEAST 40KG HAVING NO PRIOR ARV TX HISTORY OR ARE VIROLOGICALLY SUPPRESSED ON A STABLE ARV REGIMEN FOR AT LEAST 6 MO
Modulators of pharmacokinetic properties of therapeutics
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TREATMENT OF HIV-1 INFECTION USING A COMPOSITION CONTAINING A PHARMACOKINETIC ENHANCER THAT INHIBITS CYTOCHROME P450 MONOOXYGENASE IN ADULTS WHO HAVE NO PRIOR ANTIRETROVIRAL TREATMENT HISTORY
Modulators of pharmacokinetic properties of therapeutics
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TREATMENT OF HIV-1 INFECTION USING A COMPOSITION CONTAINING A PHARMACOKINETIC ENHANCER THAT INHIBITS CYTOCHROME P450 MONOOXYGENASE IN ADULTS WHO ARE VIROLOGICALLY SUPPRESSED ON A STABLE ANTIRETROVIRAL REGIMEN FOR AT LEAST 6 MONTHS
Pseudopolymorphic forms of a HIV protease inhibitor
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Tenofovir alafenamide hemifumarate
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TREATMENT OF HIV-1 INFECTION IN ADULTS WHO HAVE NO PRIOR ANTIRETROVIRAL TREATMENT HISTORY OR ARE VIROLOGICALLY SUPPRESSED ON A STABLE ANTIRETROVIRAL REGIMEN FOR AT LEAST 6 MONTHS
Tenofovir alafenamide hemifumarate
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TREATMENT OF HIV-1 INFECTION IN ADULTS AND PEDIATRIC PATIENTS WEIGHING AT LEAST 40 KG WHO HAVE NO PRIOR ANTIRETROVIRAL TREATMENT HISTORY OR ARE VIROLOGICALLY SUPPRESSED ON A STABLE ANTIRETROVIRAL REGIMEN FOR AT LEAST 6 MONTHS
Tenofovir alafenamide hemifumarate
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TREATMENT OF HIV-1 INFECTION IN ADULTS WHO HAVE NO PRIOR ANTIRETROVIRAL TREATMENT HISTORY OR ARE VIROLOGICALLY SUPPRESSED ON A STABLE ANTIRETROVIRAL REGIMEN FOR AT LEAST 6 MONTHS
Tenofovir alafenamide hemifumarate
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TREATMENT OF HIV-1 INFECTION IN ADULTS AND PEDIATRIC PATIENTS WEIGHING AT LEAST 40 KG WHO HAVE NO PRIOR ANTIRETROVIRAL TREATMENT HISTORY OR ARE VIROLOGICALLY SUPPRESSED ON A STABLE ANTIRETROVIRAL REGIMEN FOR AT LEAST 6 MONTHS
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Janssen Prods | SYMTUZA | cobicistat; darunavir; emtricitabine; tenofovir alafenamide fumarate | TABLET;ORAL | 210455-001 | Jul 17, 2018 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
Janssen Prods | SYMTUZA | cobicistat; darunavir; emtricitabine; tenofovir alafenamide fumarate | TABLET;ORAL | 210455-001 | Jul 17, 2018 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Janssen Prods | SYMTUZA | cobicistat; darunavir; emtricitabine; tenofovir alafenamide fumarate | TABLET;ORAL | 210455-001 | Jul 17, 2018 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
Janssen Prods | SYMTUZA | cobicistat; darunavir; emtricitabine; tenofovir alafenamide fumarate | TABLET;ORAL | 210455-001 | Jul 17, 2018 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Janssen Prods | SYMTUZA | cobicistat; darunavir; emtricitabine; tenofovir alafenamide fumarate | TABLET;ORAL | 210455-001 | Jul 17, 2018 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
Janssen Prods | SYMTUZA | cobicistat; darunavir; emtricitabine; tenofovir alafenamide fumarate | TABLET;ORAL | 210455-001 | Jul 17, 2018 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
Janssen Prods | SYMTUZA | cobicistat; darunavir; emtricitabine; tenofovir alafenamide fumarate | TABLET;ORAL | 210455-001 | Jul 17, 2018 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for SYMTUZA
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Janssen Prods | SYMTUZA | cobicistat; darunavir; emtricitabine; tenofovir alafenamide fumarate | TABLET;ORAL | 210455-001 | Jul 17, 2018 | ⤷ Try a Trial | ⤷ Try a Trial |
Janssen Prods | SYMTUZA | cobicistat; darunavir; emtricitabine; tenofovir alafenamide fumarate | TABLET;ORAL | 210455-001 | Jul 17, 2018 | ⤷ Try a Trial | ⤷ Try a Trial |
Janssen Prods | SYMTUZA | cobicistat; darunavir; emtricitabine; tenofovir alafenamide fumarate | TABLET;ORAL | 210455-001 | Jul 17, 2018 | ⤷ Try a Trial | ⤷ Try a Trial |
Janssen Prods | SYMTUZA | cobicistat; darunavir; emtricitabine; tenofovir alafenamide fumarate | TABLET;ORAL | 210455-001 | Jul 17, 2018 | ⤷ Try a Trial | ⤷ Try a Trial |
Janssen Prods | SYMTUZA | cobicistat; darunavir; emtricitabine; tenofovir alafenamide fumarate | TABLET;ORAL | 210455-001 | Jul 17, 2018 | ⤷ Try a Trial | ⤷ Try a Trial |
Janssen Prods | SYMTUZA | cobicistat; darunavir; emtricitabine; tenofovir alafenamide fumarate | TABLET;ORAL | 210455-001 | Jul 17, 2018 | ⤷ Try a Trial | ⤷ Try a Trial |
Janssen Prods | SYMTUZA | cobicistat; darunavir; emtricitabine; tenofovir alafenamide fumarate | TABLET;ORAL | 210455-001 | Jul 17, 2018 | ⤷ Try a Trial | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for SYMTUZA
When does loss-of-exclusivity occur for SYMTUZA?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
African Regional IP Organization (ARIPO)
Patent: 89
Estimated Expiration: ⤷ Try a Trial
Patent: 50
Estimated Expiration: ⤷ Try a Trial
Argentina
Patent: 5369
Estimated Expiration: ⤷ Try a Trial
Australia
Patent: 09242451
Estimated Expiration: ⤷ Try a Trial
Patent: 10210598
Estimated Expiration: ⤷ Try a Trial
Patent: 14221210
Estimated Expiration: ⤷ Try a Trial
Patent: 15200637
Estimated Expiration: ⤷ Try a Trial
Patent: 16250470
Estimated Expiration: ⤷ Try a Trial
Patent: 17201473
Estimated Expiration: ⤷ Try a Trial
Patent: 18267573
Estimated Expiration: ⤷ Try a Trial
Brazil
Patent: 0911871
Estimated Expiration: ⤷ Try a Trial
Patent: 1008664
Estimated Expiration: ⤷ Try a Trial
Canada
Patent: 20856
Estimated Expiration: ⤷ Try a Trial
Patent: 50521
Estimated Expiration: ⤷ Try a Trial
Chile
Patent: 11001885
Estimated Expiration: ⤷ Try a Trial
China
Patent: 2123700
Estimated Expiration: ⤷ Try a Trial
Patent: 2307573
Estimated Expiration: ⤷ Try a Trial
Patent: 3479584
Estimated Expiration: ⤷ Try a Trial
Patent: 4940937
Estimated Expiration: ⤷ Try a Trial
Colombia
Patent: 21225
Estimated Expiration: ⤷ Try a Trial
Patent: 00187
Estimated Expiration: ⤷ Try a Trial
Croatia
Patent: 0151009
Estimated Expiration: ⤷ Try a Trial
Patent: 0151357
Estimated Expiration: ⤷ Try a Trial
Cyprus
Patent: 16852
Estimated Expiration: ⤷ Try a Trial
Patent: 17067
Estimated Expiration: ⤷ Try a Trial
Denmark
Patent: 96633
Estimated Expiration: ⤷ Try a Trial
Patent: 93485
Estimated Expiration: ⤷ Try a Trial
Ecuador
Patent: 10010636
Estimated Expiration: ⤷ Try a Trial
Patent: 11011307
Estimated Expiration: ⤷ Try a Trial
Eurasian Patent Organization
Patent: 1313
Estimated Expiration: ⤷ Try a Trial
Patent: 2950
Estimated Expiration: ⤷ Try a Trial
Patent: 0123
Estimated Expiration: ⤷ Try a Trial
Patent: 1071173
Estimated Expiration: ⤷ Try a Trial
Patent: 1190125
Estimated Expiration: ⤷ Try a Trial
Patent: 1491658
Estimated Expiration: ⤷ Try a Trial
Patent: 1591353
Estimated Expiration: ⤷ Try a Trial
European Patent Office
Patent: 96633
Estimated Expiration: ⤷ Try a Trial
Patent: 93485
Estimated Expiration: ⤷ Try a Trial
Patent: 06032
Estimated Expiration: ⤷ Try a Trial
Hong Kong
Patent: 53670
Estimated Expiration: ⤷ Try a Trial
Patent: 64737
Estimated Expiration: ⤷ Try a Trial
Patent: 15679
Estimated Expiration: ⤷ Try a Trial
Hungary
Patent: 25822
Estimated Expiration: ⤷ Try a Trial
Patent: 26380
Estimated Expiration: ⤷ Try a Trial
Israel
Patent: 8614
Estimated Expiration: ⤷ Try a Trial
Patent: 4227
Estimated Expiration: ⤷ Try a Trial
Japan
Patent: 11242
Estimated Expiration: ⤷ Try a Trial
Patent: 22213
Estimated Expiration: ⤷ Try a Trial
Patent: 11927
Estimated Expiration: ⤷ Try a Trial
Patent: 25171
Estimated Expiration: ⤷ Try a Trial
Patent: 11522790
Estimated Expiration: ⤷ Try a Trial
Patent: 12517432
Estimated Expiration: ⤷ Try a Trial
Patent: 14012741
Estimated Expiration: ⤷ Try a Trial
Patent: 14221845
Estimated Expiration: ⤷ Try a Trial
Mexico
Patent: 2377
Estimated Expiration: ⤷ Try a Trial
Patent: 10011963
Estimated Expiration: ⤷ Try a Trial
Patent: 11008289
Estimated Expiration: ⤷ Try a Trial
New Zealand
Patent: 8978
Estimated Expiration: ⤷ Try a Trial
Patent: 4214
Estimated Expiration: ⤷ Try a Trial
Peru
Patent: 110994
Estimated Expiration: ⤷ Try a Trial
Poland
Patent: 96633
Estimated Expiration: ⤷ Try a Trial
Patent: 93485
Estimated Expiration: ⤷ Try a Trial
Portugal
Patent: 96633
Estimated Expiration: ⤷ Try a Trial
Patent: 93485
Estimated Expiration: ⤷ Try a Trial
San Marino
Patent: 01500266
Estimated Expiration: ⤷ Try a Trial
Singapore
Patent: 3544
Estimated Expiration: ⤷ Try a Trial
Patent: 0618
Estimated Expiration: ⤷ Try a Trial
Patent: 14007744
Estimated Expiration: ⤷ Try a Trial
Patent: 201609006W
Estimated Expiration: ⤷ Try a Trial
Patent: 201706215U
Estimated Expiration: ⤷ Try a Trial
Slovenia
Patent: 96633
Estimated Expiration: ⤷ Try a Trial
Patent: 93485
Estimated Expiration: ⤷ Try a Trial
South Africa
Patent: 1008007
Estimated Expiration: ⤷ Try a Trial
South Korea
Patent: 1645759
Estimated Expiration: ⤷ Try a Trial
Patent: 1659971
Estimated Expiration: ⤷ Try a Trial
Patent: 1738325
Estimated Expiration: ⤷ Try a Trial
Patent: 1784647
Estimated Expiration: ⤷ Try a Trial
Patent: 110015581
Estimated Expiration: ⤷ Try a Trial
Patent: 110122729
Estimated Expiration: ⤷ Try a Trial
Patent: 160093100
Estimated Expiration: ⤷ Try a Trial
Patent: 160114728
Estimated Expiration: ⤷ Try a Trial
Spain
Patent: 48886
Estimated Expiration: ⤷ Try a Trial
Patent: 53897
Estimated Expiration: ⤷ Try a Trial
Taiwan
Patent: 44367
Estimated Expiration: ⤷ Try a Trial
Patent: 1040142
Estimated Expiration: ⤷ Try a Trial
Ukraine
Patent: 1193
Estimated Expiration: ⤷ Try a Trial
Patent: 3224
Estimated Expiration: ⤷ Try a Trial
Uruguay
Patent: 424
Estimated Expiration: ⤷ Try a Trial
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering SYMTUZA around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Japan | 2002518063 | ⤷ Try a Trial | |
Australia | 2017201473 | Tablets for combination therapy | ⤷ Try a Trial |
Japan | 2018065870 | テノホビルアラフェナミドヘミフマレート (TENOFOVIR ALAFENAMIDE HEMIFUMARATE) | ⤷ Try a Trial |
Spain | 2224547 | ⤷ Try a Trial | |
European Patent Office | 2393485 | COMPRIMÉ BICOUCHE CONTENANT DE L'ELVITEGRAVIR, DU COBICISTAT, DE L'EMTRICITABINE ET DU TENOFOVIR (BILAYER TABLETS COMPRISING ELVITEGRAVIR, COBICISTAT, EMTRICITABINE AND TENOFOVIR) | ⤷ Try a Trial |
African Regional IP Organization (ARIPO) | 3639 | TENOFOVIR ALAFENAMIDE HEMIFUMARATE | ⤷ Try a Trial |
Cyprus | 1117067 | ⤷ Try a Trial | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for SYMTUZA
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1301519 | CA 2016 00012 | Denmark | ⤷ Try a Trial | PRODUCT NAME: TENOFOVIRALAFENAMID ELLER ET SALT ELLER SOLVAT DERAF, I SAERDELESHED TENOFOVIRALAFENAMIDFUMARAT; REG. NO/DATE: EU/1/15/1061/001-002 20151123 |
2487162 | 2016/063 | Ireland | ⤷ Try a Trial | PRODUCT NAME: COBICISTAT OR A PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVATE THEREOF AND DARUNAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVATE THEREOF, IN PARTICULAR DARUNAVIR ETHANOLATE; REGISTRATION NO/DATE: EU/1/14/967 20141119 |
2487163 | 122016000120 | Germany | ⤷ Try a Trial | PRODUCT NAME: COBICISTAT ODER EIN PHARMAZEUTISCHES AKZEPTABLES SALZ DAVON UND ATAZANAVIR ODER EIN PHARMAZEUTISCH AKZEPTABLES SALZ DAVON; REGISTRATION NO/DATE: EU/1/15/1025 20150713 |
1301519 | 11/2016 | Austria | ⤷ Try a Trial | PRODUCT NAME: TENOFOVIRALAFENAMID ODER EIN SALZ ODER SOLVAT DAVON, INSBESONDERE TENOFOVIRALAFENAMIDFUMARAT; REGISTRATION NO/DATE: EU/1/15/1061/001-002 (MITTEILUNG) 20151123 |
2049506 | PA2015040,C2049506 | Lithuania | ⤷ Try a Trial | PRODUCT NAME: KOBICISTATAS ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA; REGISTRATION NO/DATE: EU/1/13/830/001 - 002 20130524 |
3150586 | 2020C/515 | Belgium | ⤷ Try a Trial | PRODUCT NAME: COBICISTAT OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT OF SOLVAAT HIERVAN, DARUNAVIR OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT OF SOLVAAT HIERVAN, IN HET BIJZONDER DARUNAVIR ETHANOLATE, EN EMTRICITABINE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT OF SOLVAAT HIERVAN; AUTHORISATION NUMBER AND DATE: EU/1/17/1225 20170925 |
2049506 | CR 2015 00060 | Denmark | ⤷ Try a Trial | PRODUCT NAME: COBICISTAT ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/13/830/001-002 20130527 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |